Home › Funds › Royce & Associates › LFCR
Royce & Associates position in LFCR
LIFECORE BIOMEDICAL INC · Health Care
Latest position (Q1 2024)75.61K sh
Reported value held$401.49K
Portfolio Weight0.00%
First reportedQ3 2021
Last changeHold
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 75.61K | $697.00K | New |
| Q4 2021 | 75.61K | $839.00K | Hold |
| Q1 2022 | 75.61K | $876.00K | Hold |
| Q2 2022 | 75.61K | $754.00K | Hold |
| Q3 2022 | 75.61K | $672.00K | Hold |
| Q4 2022 | 75.61K | $490 | Hold |
| Q1 2023 | 75.61K | $285 | Hold |
| Q2 2023 | 75.61K | $731.15K | Hold |
| Q3 2023 | 75.61K | $570.48K | Hold |
| Q4 2023 | 75.61K | $468.03K | Hold |
| Q1 2024 | 75.61K | $401.49K | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding LFCR
- Vanguard Group 1.67M sh · $13.69M · Q4 2025
- BlackRock Inc 2.01M sh · $10.57M · Q2 2026
- Geode Capital Management 855.50K sh · $4.49M · Q2 2026
- Morgan Stanley 769.36K sh · $4.04M · Q2 2026
- Northern Trust Corp 253.82K sh · $1.33M · Q2 2026
- Marshall Wace 177.47K sh · $931.72K · Q2 2026
- Millennium Management 133.31K sh · $699.85K · Q2 2026
- Goldman Sachs Group 124.94K sh · $655.93K · Q2 2026
- Renaissance Technologies 104.86K sh · $550.51K · Q2 2026
- Citadel Advisors 98.87K sh · $519.07K · Q2 2026
- UBS Group AG 90.31K sh · $474.14K · Q2 2026
- Charles Schwab Investment Management 87.65K sh · $460.16K · Q2 2026